Proteins and Peptides

12 June 2014

Capstone Therapeutics Announces Initiation of Dosing for AEM-28 Phase 1b/2a Human Clinical Trial in Refractory Hypercholesterolemic Subjects

11 June 2014

Xenetic Biosciences Announces Dosing of First Patient on Dialysis in Phase 2a Clinical Study of ErepoXen(R)

11 June 2014

Portola Pharmaceuticals Announces Positive Phase 2 Data With FDA-Designated Breakthrough Therapy Andexanet Alfa and Enoxaparin

7 June 2014

FDA Approves Biogen Idec’s ELOCTATE™, First Hemophilia A Therapy to Extend the Interval between Prophylactic Infusions, for Both Adults and Children

6 June 2014

Xeris Pharmaceuticals, Inc. Announces Dosing of First Patient in Phase 2 Clinical Trial of its Investigational Soluble Glucagon for the Treatment of Mild-to-Moderate Hypoglycemia

5 June 2014

ORBACTIVTM (Oritavancin) Phase 3 Trial Results Published in New England Journal of Medicine

5 June 2014

Halozyme To Resume PEGPH20 Clinical Program In Pancreatic Cancer

3 June 2014

Thrasos Presents Preclinical Data Demonstrating THR-184 Prevents Loss of Kidney Function Following Acute Ischemic Injury

2 June 2014

Neumedicines Publishes Data Demonstrating that HemaMax(TM) (rHuIL-12), but not G-CSF, Significantly Improves Survival After Exposure to Lethal Radiation

2 June 2014

Phase 3 Data Highlight Benefits of Using VELCADE® within Frontline Treatment of Mantle Cell Lymphoma, with Results Showing Significantly Longer Progression-Free Survival Compared to Standard of Care

2 June 2014

VELCADE® (bortezomib)-based Therapy Significantly Improved Progression-Free Survival Compared to Standard Therapy as Frontline Treatment of Patients with Mantle Cell Lymphoma in Phase 3 Study

2 June 2014

Cerenis Reports Two Positive Phase II Studies for HDL Mimetic CER-001 at EAS

2 June 2014

Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, at 50th ASCO Meeting

1 June 2014

PROCLAIM(SM) National Patient Registry Analysis Shows Improved Median Overall Survival in Patients with Metastatic Melanoma Treated with High-Dose Interleukin-2 (HD IL-2)

30 May 2014

Angiochem Initiates Phase 2 Clinical Study for Lead Drug Candidate, ANG1005, in HER2+ Breast Cancer with Brain Metastases

29 May 2014

Tarsa Therapeutics Raises $7 Million To Prepare For Filing NDA For Ostora, Its Oral Calcitonin For The Treatment Of Postmenopausal Osteoporosis

28 May 2014

Spectrum Pharmaceuticals Completes Enrollment in Phase 2 Trial of SPI-2012 – A Novel Long-Acting Granulocyte Colony Stimulating Factor (GCSF) to Treat Chemotherapy-induced Neutropenia

27 May 2014

BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease

26 May 2014

European Medicines Agency (EMA) adopts positive opinion on Octapharma’s human cell line recombinant human FVIII (Nuwiq®) in children and adults with haemophilia A

24 May 2014

FDA Approves Durata Therapeutics’ DALVANCE(TM) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Caused by Susceptible Gram-Positive Bacteria, Including MRSA, in Adults

23 May 2014

Novartis provides update on EU marketing authorization application for RLX030 in acute heart failure

23 May 2014

CHMP Adopts Positive Opinion for PLEGRIDY™ (Peginterferon Beta-1a) as a Treatment for Multiple Sclerosis in the European Union

22 May 2014

Data on Angiox (Bivalirudin Injection) in Heart Attack Patients Presented at EuroPCR and Published in European Heart Journal

21 May 2014

aTyr Pharma Completes First Phase 1 Study For Rare Disease Program

19 May 2014

Trevena Highlights Phase 2b-BLAST AHF Trial for TRV027 at the European Society of Cardiology Heart Failure 2014 Meeting

16 May 2014

Phase 3a data from largest trial with liraglutide 3 mg demonstrated significantly greater weight loss versus placebo for adults with obesity

16 May 2014

Kamada Announces Preliminary Results from Phase II/III Pivotal Trial in Europe and Canada of Inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency

16 May 2014

FDA issues Complete Response Letter for RLX030 for acute heart failure

15 May 2014

Transition Therapeutics Diabetes Drug Candidate, TT-401, Commences Phase 2 Clinical Study

15 May 2014

LFB SA Announces That First Patient Has Begun Treatment with New Coagulation Factor VIIa (Recombinant) in Global Phase 3 Clinical Trial in Hemophilia A and B with Inhibitors

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

DLL3-Targeted Immunotherapy Candidates Pipeline Review

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

5T4-Targeted Immunotherapy Candidates Pipeline Review

CD47 and SIRP-alpha Targeted Immunotherapy Pipeline Review

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review

Report Package: “Drug the Undruggable” Technologies

Biologics Sales Database for Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and RNA

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis